Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lexicon Pharmaceuticals (LXRX)
NASDAQ:LXRX
RESEARCH TOOLSreports
Holding LXRX?
Track your performance easily
LXRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.86 - $3.73
Previous Close$0.88
Volume3.13M
Average Volume (3M)3.16M
Market Cap
$318.44M
Enterprise Value$159.97M
Total Cash (Recent Filing)$258.37M
Total Debt (Recent Filing)$99.90M
Price to Earnings (P/E)―
Beta2.34
Next Earnings
Mar 12, 2025EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding361,492,295
10 Day Avg. Volume3,280,360
30 Day Avg. Volume3,157,224
Standard Deviation0.30
R-Squared0.05
Alpha0.00893
Financial Highlights & Ratios
Price to Book (P/B)1.80
Price to Sales (P/S)67.12
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue42.80
Enterprise Value/Gross Profit142.96
Enterprise Value/Ebitda-0.83
Forecast
1Y Price Target
$7.00Price Target Upside766.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Lexicon Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Pipeline PotentialLX9851 aims to ameliorate current obesity treatments, positioning it as a potential game changer in weight management.
Regulatory ProgressThe briefing documents did not reveal negative surprises such as requests for additional post-marketing studies or new safety concerns.
Strategic PartnershipsThe partnership with Viatris broadens sota’s global commercialization potential, particularly with a partner experienced in launching various therapeutics.
Bears Say
Market Performance3Q24 Inpefa sales were $1.7M, below expectations and consensus.
Regulatory ChallengesThe negative AdCom vote for sotagliflozin in T1D/CKD makes US approval unlikely.
Safety ConcernsThe FDA's questions raised concerns about the characterization of the risk of DKA associated with sotaglifozin.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $0.86 and its highest was $3.73 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Currently, no data Available
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Mar 12, 2025 which is in 111 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.163 by -$0.017.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -$0.13.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 361,492,300 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.163. Following the earnings report the stock price went down -8.403%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Among the largest hedge funds holding Lexicon Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Lexicon Pharmaceuticals’s shares valued at N/A.
---
Lexicon Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (766.98% Upside)
$7.00 (766.98% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 427.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.42%
12-Months-Change
Fundamentals
Return on Equity
-135.14%
Trailing 12-Months
Asset Growth
16.15%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.
---
LXRX Earnings Call
Q3 2024
0:00 / 0:00
---
LXRX Stock 12 Month Forecast
Average Price Target
$7.00
▲(766.98% Upside)
Technical Analysis
Best Analysts Covering LXRX
1 Year
1 Year Success Rate
6/19 ratings generated profit
1 Year Average Return
-13.41%
reiterated a buy rating 7 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 31.58% of your transactions generating a profit, with an average return of -13.41% per trade.
---